Trial Profile
A multi-center, open-label, single-Arm, phase 1, dose escalation study of ASONEP (sonepcizumab/LT1009) administered as a single agent weekly to subjects with refractory advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2015
Price :
$35
*
At a glance
- Drugs Sonepcizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Lpath
- 30 Mar 2010 Status changed from active, no longer recruiting to completed, as reported in an Lpath media release.
- 09 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 May 2008 New trial record.